Abstract: The invention relates to ruxolitinib crystal and a pharmaceutical composition thereof. In particular, the invention provides ruxolitinib dihydrate crystal and a preparation method thereof, and ruxolitinib free base in amorphous form and a preparation method thereof, and a pharmaceutical composition comprising ruxolitinib dihydrate crystal or ruxolitinib free base in amorphous form. The crystal, amorphous form and pharmaceutical composition of the invention have simple preparation method, high product yield, and excellent crystal stability, hygroscopicity and processability, and thus are suitable for industrial production.

Abstract: High solids coating compositions are disclosed, based on polymeric resins synthesized by polycondensation or by solution Free Radical Polymerization FRP and/or Atom Transfer Radical Polymerization ATRP. Two pack coatings with low volatile organic content (VOC) are provided, by curing the above mentioned hydroxy functional polymers, also containing other chemical functional groups in the backbone or side chains (such as oxirane, amino, allyl, halogen) with polyisocyanates and/or amino resins cross-linkers. The coatings thus formulated contain less than about 50% by weight of an organic solvent when applied.